Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis

Bruce Lee, Ann E. Wiringa, Rachel R. Bailey, G. Jonathan Lewis, Jared Feura, Robert R. Muder

Research output: Contribution to journalArticle

Abstract

To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [≤$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy ≥30%, and a $100 vaccine at vaccine efficacy ≥70%. High MRSA prevalence (≥25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.

Original languageEnglish (US)
Pages (from-to)2465-2471
Number of pages7
JournalVaccine
Volume28
Issue number12
DOIs
StatePublished - Mar 11 2010
Externally publishedYes

Fingerprint

Economic Models
econometric models
orthopedics
economic analysis
Orthopedics
Staphylococcus aureus
Vaccines
vaccines
Methicillin-Resistant Staphylococcus aureus
Costs and Cost Analysis
Computer Simulation
Economics
quality-adjusted life year
Quality-Adjusted Life Years
economic valuation
computer simulation
simulation models
surgery
economics

Keywords

  • Computer simulation
  • Economics
  • Orthopedic surgery
  • Staphylococcus aureus
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Lee, B., Wiringa, A. E., Bailey, R. R., Lewis, G. J., Feura, J., & Muder, R. R. (2010). Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis. Vaccine, 28(12), 2465-2471. https://doi.org/10.1016/j.vaccine.2009.12.075

Staphylococcus aureus vaccine for orthopedic patients : An economic model and analysis. / Lee, Bruce; Wiringa, Ann E.; Bailey, Rachel R.; Lewis, G. Jonathan; Feura, Jared; Muder, Robert R.

In: Vaccine, Vol. 28, No. 12, 11.03.2010, p. 2465-2471.

Research output: Contribution to journalArticle

Lee, B, Wiringa, AE, Bailey, RR, Lewis, GJ, Feura, J & Muder, RR 2010, 'Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis', Vaccine, vol. 28, no. 12, pp. 2465-2471. https://doi.org/10.1016/j.vaccine.2009.12.075
Lee, Bruce ; Wiringa, Ann E. ; Bailey, Rachel R. ; Lewis, G. Jonathan ; Feura, Jared ; Muder, Robert R. / Staphylococcus aureus vaccine for orthopedic patients : An economic model and analysis. In: Vaccine. 2010 ; Vol. 28, No. 12. pp. 2465-2471.
@article{4b5e089da55d4a63b5c5a3751e35e75b,
title = "Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis",
abstract = "To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1{\%}, a $50 vaccine was cost-effective [≤$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy ≥30{\%}, and a $100 vaccine at vaccine efficacy ≥70{\%}. High MRSA prevalence (≥25{\%}) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.",
keywords = "Computer simulation, Economics, Orthopedic surgery, Staphylococcus aureus, Vaccine",
author = "Bruce Lee and Wiringa, {Ann E.} and Bailey, {Rachel R.} and Lewis, {G. Jonathan} and Jared Feura and Muder, {Robert R.}",
year = "2010",
month = "3",
day = "11",
doi = "10.1016/j.vaccine.2009.12.075",
language = "English (US)",
volume = "28",
pages = "2465--2471",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "12",

}

TY - JOUR

T1 - Staphylococcus aureus vaccine for orthopedic patients

T2 - An economic model and analysis

AU - Lee, Bruce

AU - Wiringa, Ann E.

AU - Bailey, Rachel R.

AU - Lewis, G. Jonathan

AU - Feura, Jared

AU - Muder, Robert R.

PY - 2010/3/11

Y1 - 2010/3/11

N2 - To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [≤$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy ≥30%, and a $100 vaccine at vaccine efficacy ≥70%. High MRSA prevalence (≥25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.

AB - To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [≤$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy ≥30%, and a $100 vaccine at vaccine efficacy ≥70%. High MRSA prevalence (≥25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.

KW - Computer simulation

KW - Economics

KW - Orthopedic surgery

KW - Staphylococcus aureus

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77249155107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249155107&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.12.075

DO - 10.1016/j.vaccine.2009.12.075

M3 - Article

C2 - 20064479

AN - SCOPUS:77249155107

VL - 28

SP - 2465

EP - 2471

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 12

ER -